View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Oct. 19 (HealthDay News) -- The composition of placebos used in clinical trials -- including pills, injectables, and other substances -- are not regulated and rarely reported, which may ultimately compromise the integrity of clinical research, according to a study in the Oct. 19 issue of the Annals of Internal Medicine.
Beatrice A. Golomb, M.D., of the University of California San Diego School of Medicine, and colleagues conducted a study of placebos used in clinical trials published in four high-impact, English-language general and internal medicine journals. There are no regulations governing the composition of placebos, and the researchers wanted to determine how often investigators include information about the composition of these substances in published clinical trials.
The reviewed journals included 167 eligible studies, of which the majority included either pill or injection placebos. The researchers found that the composition of pills, injections, and other approaches were revealed in 8.24, 26.3, and 27.8 percent of journal articles, respectively.
"In conclusion, failure to describe placebo ingredients breaches basic scientific standards of rigor," the authors write. "Because inferences from clinical trials propagate to clinical practice, failure to report placebo composition compromises the foundation on which medical decisions are based, and on which the fate of lives may rest."
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top